---
category: news
title: "Lantern Pharma Announces Launch of Antibody Drug Conjugate (ADC) Program to Target Solid Tumors & Blood Cancers through Agreement with Califia Pharma"
excerpt: "PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR Â® artificial intelligence (\"A.I.\") platform to transform cancer drug development and identify patients who will benefit from its targeted oncology therapeutics,"
publishedDateTime: 2021-01-04T12:30:00Z
originalUrl: "https://markets.businessinsider.com/news/stocks/lantern-pharma-announces-launch-of-antibody-drug-conjugate-adc-program-to-target-solid-tumors-blood-cancers-through-agreement-with-califia-pharma-1029930022"
webUrl: "https://markets.businessinsider.com/news/stocks/lantern-pharma-announces-launch-of-antibody-drug-conjugate-adc-program-to-target-solid-tumors-blood-cancers-through-agreement-with-califia-pharma-1029930022"
type: article
quality: 15
heat: 15
published: false

provider:
  name: Business Insider
  domain: businessinsider.com
  images:
    - url: "https://smartableai.github.io/artificial-intelligence/assets/images/organizations/businessinsider.com-50x50.jpg"
      width: 50
      height: 50

topics:
  - AI in Healthcare
  - AI

images:
  - url: "https://mma.prnewswire.com/media/1216507/Lantern_Pharma_Logo.jpg"
    width: 400
    height: 296
    isCached: true

secured: "dw3vY3Xi+5FSlqUK29Y1tnfpRHCU1dAcJ4S1g5wdNtdQeZCh2/rEctP7gJ0J8S32Ricf5PpjX17aoFWwqI+PeWG/GEzKSrFHPERgDChlCdavdrGgJGZ2v8CrNzZzLuYqDVZjLu1cyPWQ98qktBLEscsMTuCwLEMVGQGHL0gHFSzEhN5eZqg5BbkETCWc5noUg+nfWKcqPoUi47/WLnLKLNOE7nI/54VztF90IaFK08+qXsd6qvpzL4rUzn1aaAhoqMvQiUa91mUWfLBRDRoD6YV6Td1DouyyO3mWEuP/Yi14DWqc2kxB8Lj4jrZ2deFRWFI999epiNq8pzlwF77sqYTwA3sTbMPdbOiv5s7jE2w=;b/W2qb6XgJSPowkbfuLB8g=="
---

